Drug Profile
Research programme: bone-targeted mTOR inhibitors - Takeda
Alternative Names: AP 23675; AP 23841; AP 24170Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Developer Takeda
- Class Antineoplastics
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone cancer
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 08 Jul 2009 No development reported - Preclinical for Bone cancer in USA (unspecified route)
- 01 May 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the pharmacokinetics and Cancer pharmacodynamics section ,